Polyrizon Signs MOU to Acquire 51% Stake in Arrow Aviation
Polyrizon announced the signing of a non-binding Memorandum of Understanding with Arrow Aviation, a global private aviation company. Under the terms of the MOU, Polyrizon intends to acquire a 51% stake in Arrow Aviation on a fully diluted basis through a cash investment of NIS 18M, or approximately $5M, marking a strategic expansion into the high-growth private aviation sector. The company said, "Arrow Aviation, with annual unaudited revenues of approximately $19M and adjusted EBITDA of approximately $3M, is a leading provider of private aviation services, operating a fleet of executive jets and delivering uncompromising, high-standard VIP flights tailored to diverse needs. Arrow Aviation offers private flights for leisure or business, including destination stays, escorts, and seamless connections to subsequent destinations. Its services extend to the public sector, supporting government offices and public entities with specialized flights, such as ambulance and medical evacuations, air rescues, special-needs transport, medical tourism, and cargo operations, including the handling of sensitive and hazardous materials under special licenses. Arrow Aviation serves business, private, and public clients with personalized, point-to-point solutions, underpinned by a passion for aviation, extensive industry expertise, and a full operational infrastructure featuring a complete aircraft fleet and dozens of highly skilled pilots holding professional licenses for private, commercial, hazardous materials, and other specialized flights.: The proposed transaction includes ancillary arrangements, such as the transfer of a Hawker 800 aircraft valued at $3.5M to Arrow Aviation by a third party, in exchange for a convertible note issued by Polyrizon. Additionally, existing Arrow Aviation shareholders will forgive outstanding shareholder debts owed by Arrow Aviation in return for convertible notes from Polyrizon, enabling Arrow Aviation to emerge debt-free from institutional obligations post-closing. The MOU also outlines mutual call and put options on the remaining 49% of Arrow Aviation's shares, exercisable after two years, based on agreed valuation multiples tied to financial metrics like EBITDA or revenue, which may result in Polyrizon acquiring 100% of Arrow Aviation on a fully diluted basis. The signing of a definitive agreement is expected to occur within 30 days of the MOU, subject to due diligence, after which the closing of the acquisition would be expected to occur following the satisfaction of customary closing conditions.
Trade with 70% Backtested Accuracy
Analyst Views on PLRZ
About PLRZ
About the author

- Strategic Acquisition Plan: Polyrizon intends to acquire a 51% stake in Arrow Aviation through a cash investment of NIS 18 million (approximately $5.8 million), marking a strategic expansion into the high-growth private aviation market, which is projected to reach $41.38 billion by 2030.
- Arrow Aviation Overview: With annual revenues of approximately $19 million and adjusted EBITDA of about $3 million, Arrow Aviation is a leading provider of private aviation services, offering high-standard VIP flights that cater to diverse needs, thereby enhancing Polyrizon's competitive edge in the market.
- Debt Forgiveness Arrangement: As part of the transaction, existing shareholders of Arrow Aviation will forgive outstanding debts in exchange for convertible notes issued by Polyrizon, enabling Arrow Aviation to operate debt-free post-closing, thus improving its financial health.
- Future Growth Potential: The MOU includes mutual call and put options on the remaining 49% of Arrow Aviation's shares, based on agreed valuation multiples tied to financial metrics, potentially allowing Polyrizon to fully acquire Arrow Aviation in the future, further strengthening its market position in the aviation sector.
- Strategic Diversification: Polyrizon Ltd. has signed a non-binding MOU to acquire a 51% stake in Arrow Aviation Ltd. for NIS 18 million (approximately $5.8 million), marking a strategic entry into the high-growth private aviation sector.
- Financial Performance: Arrow Aviation generates approximately $19 million in annual revenue and $3 million in adjusted EBITDA, providing various services including medical evacuations and special-needs transport, enhancing Polyrizon's market potential in aviation.
- Debt Restructuring: As part of the transaction, Arrow Aviation's existing shareholders will forgive outstanding loans in exchange for Polyrizon's convertible notes, allowing Arrow Aviation to achieve a debt-free status post-closing, further optimizing its financial structure.
- Market Outlook: Industry forecasts project the private aviation market to reach $41.38 billion by 2030, aligning Polyrizon's acquisition strategy with its exploration of revenue-generating opportunities in high-growth sectors, which is expected to yield significant revenue growth for the company.
- Strategic Expansion: Polyrizon has signed a non-binding MOU with Arrow Aviation to acquire a 51% stake through a cash investment of NIS 18 million (approximately $5.8 million), marking a strategic move into the high-growth private aviation sector.
- Financial Background: Arrow Aviation generates approximately $19 million in annual revenue with an adjusted EBITDA of $3 million, providing high-quality VIP flight services that cater to a diverse clientele, showcasing its competitive position in the market.
- Market Potential: This acquisition will enable Polyrizon to enter the rapidly growing private aviation market, with expectations to drive future revenue growth and market share expansion by integrating Arrow Aviation's resources and customer base.
- Investment Intent: Through this investment, Polyrizon not only strengthens its business footprint in the aviation sector but also demonstrates its commitment to the high-end service market, aiming to leverage the growth potential of private aviation services to achieve long-term strategic objectives.

- Strategic Investment Exploration: Polyrizon's Board has authorized the exploration of strategic investment opportunities in high-potential sectors, particularly in defense, aviation, and artificial intelligence, aiming to generate near-term revenues and enhance financial stability through selective investments.
- Commitment to Core Medical: The company remains focused on its core medical device activities, advancing the development and clinical studies of products like PL-14 (allergy blocker) and PL-16 (viral blocker), ensuring ongoing innovation and competitiveness in the medical field.
- Strong Financial Position: With a robust cash flow and a debt-free balance sheet, Polyrizon is well-positioned to efficiently utilize resources to accelerate growth and create long-term shareholder value while maintaining full focus on its primary medical pipeline.
- Technological Innovation Development: Polyrizon is developing its proprietary Capture and Contain TM hydrogel technology, which aims to provide a barrier against viruses and allergens through nasal sprays, further enhancing its market position in the biomedical field.

- Preclinical Study Results: Polyrizon's PL-14 Allergy Blocker demonstrated significant allergen-blocking performance in a new in-vitro study, effectively reducing allergen transfer compared to hydroxypropyl methylcellulose (HPMC) at all time points, indicating its potential to form an effective intranasal hydrogel barrier that minimizes allergen exposure to nasal tissue.
- Advancement of Development Program: Following these positive results, the company plans to advance its preclinical development program and support future clinical studies aimed at establishing PL-14's regulatory pathway and real-world clinical benefits for allergy prevention, positioning it as a viable solution in the market.
- Positive Market Reaction: In response to the favorable news, Polyrizon's stock rose 5.65% to $13.47 on Nasdaq, reflecting investor confidence in the company's research progress and market potential.
- Strategic Implications: The successful development of PL-14 could not only transform the landscape of allergy treatment but also enhance Polyrizon's competitiveness in the biopharmaceutical sector, further driving the company's positioning in the allergy prevention market.
- Efficacy Validation: The PL-14 formulation significantly reduced the transfer of the major allergen Der p 1 compared to the standard comparator HPMC, with allergen concentrations at 1 hour being approximately 20.6 ng versus HPMC's 1354.4 ng, indicating its potential as a new preventive solution for allergic rhinitis.
- Sustained Protective Effect: At 4 hours, PL-14 reached a maximum allergen concentration of about 141.2 ng while maintaining low levels across all time points, demonstrating its sustained protective capability against allergen exposure to nasal tissue, which enhances its market competitiveness.
- R&D Advancement: The study utilized a validated in-vitro permeability system, ensuring data reliability and supporting further development of PL-14 as a potential preventive approach for allergic rhinitis, potentially laying the groundwork for future clinical studies.
- Market Potential: Polyrizon plans to continue advancing PL-14's preclinical development to establish its regulatory pathway and real-world clinical benefits, reflecting the company's commitment to the allergy market and its long-term growth potential.







